Physician Locator

Welcome to the Physician Locator—an online listing of healthcare providers who may treat moderate to severe persistent allergic asthma. Here you'll find all you need to help connect your patients with local physicians.


Add your practice to the directory by creating a profile below. Any information you provide is used solely to help patients find a physician. It will not be disclosed to third parties.


A severe allergic reaction called anaphylaxis has happened in some patients after they received XOLAIR.
Click here for more important safety information about XOLAIR.


Get started by creating your profile or logging in to manage your account.


ADD YOUR PRACTICE

Join in 2 easy steps.

First, fill out your professional details. Then complete your profile by entering your office location and contact information.

CREATE YOUR PROFILE
SEARCH THE DIRECTORY

Help connect your patients with local physicians.

OR
 
   I agree to the Terms & Conditions GO
ALREADY A MEMBER?

Managing your account is simple.

LOG IN

Forgot your password?
Forgot which e-mail address we have on file?

INDICATION
XOLAIR® (omalizumab) for subcutaneous use is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients.

Important Limitations of Use
XOLAIR is not indicated for treatment of other allergic conditions
XOLAIR is not indicated for the relief of acute bronchospasm or
status asthmaticus
XOLAIR is not indicated for use in pediatric patients less than
12 years of age

IMPORTANT SAFETY INFORMATION

WARNING: Anaphylaxis

Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur (see Warnings and Precautions: Anaphylaxis).

XOLAIR should only be administered in a healthcare setting by healthcare providers prepared to manage anaphylaxis that can be life-threatening.
XOLAIR should not be administered to patients who have experienced a severe hypersensitivity reaction to XOLAIR or any ingredient of XOLAIR (see Warnings and Precautions). XOLAIR should be discontinued in patients who experience a severe hypersensitivity reaction.
Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR-treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of asthma and other allergic disorders.
XOLAIR has not been shown to alleviate asthma exacerbations acutely. Do not use XOLAIR to treat acute bronchospasm or status asthmaticus.
A constellation of signs and symptoms including arthritis/arthralgia, rash (urticaria or other forms), fever and lymphadenopathy similar to serum sickness have been reported in post-approval use of XOLAIR in some patients. Physicians should stop XOLAIR if a patient develops this constellation of signs and symptoms.
Patients should be given and instructed to read the accompanying Medication Guide before starting treatment and before each subsequent treatment.
Do not abruptly discontinue corticosteroid use upon initiation of XOLAIR therapy. Decrease corticosteroids gradually under the direct supervision of a physician.
In patients ≥12 years of age, the most commonly observed adverse reactions (>1% more frequent in XOLAIR-treated patients) from 4 placebo-controlled asthma studies were arthralgia (8%), pain (general) (7%), leg pain (4%), fatigue (3%), dizziness (3%), fracture (2%), arm pain (2%), pruritus (2%), dermatitis (2%), and earache (2%).
The adverse events most frequently resulting in clinical intervention (e.g. discontinuation of XOLAIR, or the need for concomitant medication to treat an adverse event), in either placebo-controlled or other controlled asthma studies, were injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These events were observed at similar rates in XOLAIR-treated patients and control patients.

showmap


Log In

Forgot your password?
Forgot which e-mail address we have on file?

LOG IN
triger

Forgot Which E-Mail
Address We Have On File?

Complete the fields below to display the e-mail address we have on file for your profile.
*INDICATES A REQUIRED FIELD

SUBMIT
triger

Forgot Which E-Mail
Address We Have On File?

Your e-mail address on file is:

 

CONTINUE LOG IN

E-Mail This Page

Share this information with colleagues

To send this link to another healthcare professional, please fill out the form below.
*INDICATES A REQUIRED FIELD

SUBMIT
triger

Thank you for sharing with a colleague

 

CLOSE

DEACTIVATE YOUR ACCOUNT

Are you sure that you want to deactivate your account? You will no longer appear in the Physician Locator.

 

DEACTIVATECANCEL
triger

DEACTIVATE YOUR ACCOUNT

Your account has been deactivated. You will no longer appear in the Physician Locator.

 

OK

TERMS AND CONDITIONS



The XOLAIR® Physician Locator (the "Locator") is compiled and published by Genentech, Inc. and Novartis Pharmaceuticals Corporation (referred to as "the Companies") as a reference source of demographic and professional information on certain individual physicians in the United States. The only permitted uses of the Locator are for: (i) the personal convenience of individual members of the general public to facilitate quick access to information about physicians with whom they may be consulting regarding medical services; and (ii) individual physicians or their staff to add, update, or view their personal listings or those of colleagues for professional purposes such as patient referrals. Neither the Locator nor any of its data, listings, or other constituent elements may be downloaded, republished, resold, duplicated, used, or reused, in whole or in part, for any purpose other than the personal uses permitted above.

You cannot use the Locator to verify credentials of any particular physician. The database of physician information that is used to compile and publish the Locator does not contain sufficient information with which to verify physician credentials. Inclusion in this database is based on a physician’s response to a communication to all allergists and pulmonologists in the American Academy of Allergy, Asthma and Immunology list. This database is compiled for informational purposes only.

You should conduct your own inquiry concerning the credentials of any physician before consulting that physician regarding medical services. Your selection of a physician is your sole responsibility and is a decision that should be undertaken with care. For example, you may consider checking credentials with the appropriate medical boards. In addition, you can obtain names of other physicians (not listed within the Locator) by contacting a medical society.

The Companies disclaim any responsibility to update or otherwise maintain the information contained in the Locator. Furthermore, because the Companies: (i) compile such information from independent sources over whom the Companies have no control, and (ii) may experience reporting and processing errors or delays with respect to the information obtained through this Web site including, without limitation, the implied warranties of merchantability and fitness for any particular purpose. The material included in this Web site is for informational purposes only.

Inclusion of a physician is not and does not imply referral, endorsement, or recommendation by the Companies, nor does the omission of any individual indicate disapproval by the Companies.

The Companies shall not be liable to you or others for any decisions made or action taken by you or others in reliance on the information obtained from this Web site.

 

Close